Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Comment Period Open for FDA Draft Guidance on Osteoporosis Treatments; Plus FDA Rejects Abuse-Deterrent Apadaz

Michele B. Kaufman, PharmD, BCGP  |  June 22, 2016

The FDA is currently accepting comments on a draft guideline for osteoporosis treatments, which calls for more research into the long-term effects of drugs on bone quality. Also, the FDA has rejected an application for approval of Apadaz in its current form…

Filed under:AnalgesicsConditionsDrug UpdatesOsteoarthritis and Bone DisordersPain Syndromes Tagged with:Benzhydrocodone hydrochlorideChronic painFDAFood and Drug AdministrationGuidelinesOsteoporosispostmenopauseRegulation

Doctors Blame Many Factors for Futile Care, Themselves Included

Randi Belisomo  |  June 20, 2016

(Reuters Health)—Doctors who were asked about causes of inappropriate care at the end of life didn’t have to look far to place blame. They blamed themselves. Australian researchers interviewed 96 physicians from 10 medical specialties and asked them to describe situations when patients received end of life care that the doctors felt was inappropriate. Futile…

Filed under:ConditionsPractice Support Tagged with:end-of-lifefutile medical treatmentmortalitypatient carephysician

The Pay Disparity: Rheumatologist Pay Is Up, but It’s Still a Lower-Paid Specialty

Richard Quinn  |  June 17, 2016

According to a new report, rheumatology remains one of the lowest-paid specialties in medicine—despite an average pay increase of 12% over the past year. And only 44% of rheumatologists would choose the field again. Anne Bass, MD, says administrative red tape and other factors contribute to the lack of satisfaction…

Filed under:Career DevelopmentProfessional Topics Tagged with:CareerCareer satisfactionjob satisfactionrheumatologistsSalary

French Prosecutors Open Probe into Fatal Drug Trial

Reuters Staff  |  June 15, 2016

PARIS (Reuters)—Paris prosecutors said on Tuesday they have begun an involuntary manslaughter investigation into a failed drug trial that left one dead and five hospitalized in January. The prosecutors’ office said the investigation had been opened to determine whether there was a criminal element in any mistakes made or whether it was simply the result…

Filed under:Drug Updates Tagged with:cannabisclinical trialsFranceInternationalmarijuanamortality

Adalimumab & Infliximab Remain in Newborns after Delivery

Michele B. Kaufman, PharmD, BCGP  |  June 15, 2016

A recent study showed that, when administered during pregnancy, infliximab takes longer to clear an infant’s system than adalimumab…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabAnti-TNFinflammatory bowel diseaseinfliximabpregnancy

Opinion: Erosive Changes Questioned in RA/Lupus Overlap Syndrome

George A.W. Bruyn, MD, PhD  |  June 13, 2016

I read with interest the Diagnostic View (TR, April), which, according to the authors, represented a case of rhupus, an overlap syndrome of RA and SLE. I challenge this view. My arguments: In the case of erosive RA, typically erosive changes are seen at MTP joints other than MTP1 (e.g., MTP5). In addition, the erosive…

Filed under:ConditionsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ArthritiserosionLupusMTP jointRheumatoid arthritisrhupusSLEsyndromeUric acid

Rheumatoid Arthritis & Autoimmune Glomerulonephritis

Rheumatoid Arthritis & Autoimmune Glomerulonephritis

Diana M. Girnita, MD, PhD, Shahzad Safdar, MD, & Avis Ware, MD  |  June 13, 2016

Rheumatoid arthritis (RA) is rarely associated with renal manifestations, but secondary amyloidosis due to chronic inflammation is reported to be the etiology of renal dysfunction in many cases of RA.1,2 The discovery of biologic therapy, with TNF-alpha inhibitors in particular, made a huge difference in the disease course and prognosis of RA patients. However, TNF-alpha…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Autoimmunecase reportClinicalDiagnosisGlomerulonephritisimmune complexpatient careRenalRheumatoid arthritisrheumatologyTNF-Alpha inhibitor

Christopher Ritchlin Balances Patient Care with Beekeeping Hobby

Carol Patton  |  June 13, 2016

When Christopher Ritchlin, MD, MPH, isn’t teaching students, residents and fellows at the University of Rochester Medical Center (URMC), treating patients or conducting medical research in his lab, he’s monitoring the health of another sort of patient—honeybees. For the past four years. Dr. Ritchlin, professor and chief of allergy, immunology and rheumatology at URMC, has…

Filed under:Professional TopicsProfiles Tagged with:beekeepingChristopher RitchlinhobbyProfilesrheumatologist

Rheumatology Drug Updates: Etanercept for Pediatric Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  June 13, 2016

Etanercept Submitted for Chronic, Severe Plaque Psoriasis in Children The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application for etanercept (Enbrel) for treating pediatric patients with chronic, severe plaque psoriasis.1 The application was submitted in early January 2016 and is based on results of a one-year Phase 3 study with…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPediatric Conditions Tagged with:ApprovalsBiologicsBiosimilarsclinical trialsdrugetanerceptFDAknee painOsteoarthritisPediatricplaquePsoriasisrheumatologySafety

ARHP Past Presidents Share Ties to Tucson, Arizona

Ann-Marie Lindstrom  |  June 13, 2016

The American College of Rheumatology (ACR) recognized the 50th anniversary of the Association of Rheumatology Health Professionals (ARHP) during the ACR/ARHP Annual Meeting this past November in San Francisco. The University of Arizona Arthritis Center followed up with a reception in Tucson to honor past presidents of the ARHP. The Tucson area has the highest…

Filed under:Career DevelopmentProfessional Topics Tagged with:AC&RAmerican College of Rheumatology (ACR)Association of Rheumatology Professionals (ARP)Career developmentProfilesrheumatologistTucson

  • « Previous Page
  • 1
  • …
  • 211
  • 212
  • 213
  • 214
  • 215
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences